From Virchow's triad to metastasis: Circulating hemostatic factors as predictors of risk for metastasis in solid tumors

Journal of B.U.ON.

Volumn 18, Issue 1, 2013, Pages 25-33

  Beleva, Elina A ^a   Grudeva Popova, J ^a  

^a UNIVERSITY HOSPITAL ST GEORGE   (Bulgaria)

Author keywords

Angiopoietin; Cancer; Microparticles; Tissue factor; uPAR

Indexed keywords

ANGIOPOIETIN RECEPTOR; CXCL1 CHEMOKINE; INTERLEUKIN 1; INTERLEUKIN 8; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P53; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN C;

BREAST CANCER; CANCER SURVIVAL; CELL INTERACTION; CELL MIGRATION; COLORECTAL CANCER; EPITHELIUM CELL; ESOPHAGUS CANCER; FIBRINOLYSIS; GYNECOLOGIC CANCER; HUMAN; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PERICYTE; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; URINARY TRACT CANCER;

BLOOD COAGULATION; FIBRINOLYSIS; HEMOSTASIS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84879007014     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Chew H, Wun T, Harvey D et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166:458-464.
2. Mandala M, Falanga A, Roila F, Group EGW. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (S)6: vi85-92.
3. Lee A, Levine M. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107(23 S1):I17-21.
4. Grudeva-Popova J. Cancer and venous thromboembolism. J BUON 2005; 10:483-489. (Pubitemid 43285551)
5. Adcock D, Fink L, Marlar R et al. The hemostatic system and malignancy. Clin Lymphoma Myeloma 2008; 8:230-236.
6. Chu A. Tissue factor, blood coagulation, and beyond: an overview. Int J Inflam 2011; 2011:367284. Published online 2011 September 20,doi: 10.4061/2011/367284
7. Drake T, Morrissey J, Edgington T. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134:1087-1097. (Pubitemid 19142892)
8. Rickles F, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102:215-224.
9. Egorina E, Sovershaev M, Bjørkøy G et al. Intracellular and surface distribution of monocyte tissue factor: application to intersubject variability. Arterioscler Thromb Vasc Biol 2005; 25:1493-1498. (Pubitemid 40923374)
10. Hembrough T, Swartz G, Papathanassiou A et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003; 63:2997-3000. (Pubitemid 36667175)
11. Liu Y, Jiang P, Capkova K et al. Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res 2011; 71:6492-6502.
12. Lwaleed B, Cooper A. Tissue factor expression and multidrug resistance in cancer: two aspects of a common cellular response to a hostile milieu. Med Hypotheses 2000; 55:470-473.
13. Poon R, Lau C, Ho J et al. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 2003; 9:5339-5345. (Pubitemid 37413589)
14. Khorana A, Ahrendt S, Ryan C et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13:2870-2875. (Pubitemid 46849560)
15. Yu J, May L, Lhotak V et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105:1734-1741. (Pubitemid 40223697)
16. Rong Y, Belozerov V, Tucker-Burden C et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res 2009; 69:2540-2549.
17. Provençal M, Berger-Thibault N, Labbé D et al. Tissue factor mediates the HGF/Met-induced anti-apoptotic pathway in DAOY medulloblastoma cells. J Neurooncol 2010; 97:365-372.
18. Milsom C, Anderson G, Weitz J et al. Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost 2007; 5:2550-2552. (Pubitemid 350154368)
19. Milsom C, Yu J, Mackman N et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res 2008; 68:10068-10076.
20. Carmeliet P, Mackman N, Moons L et al. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383(6595):73-75. (Pubitemid 26296462)
21. Zhang Y, Deng Y, Luther T et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94:1320-1327. (Pubitemid 24286478)
22. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012; 119:924-932.
23. Liu Y, Mueller B. Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. Biochem Biophys Res Commun 2006; 344:1263-1270.
24. Hjortoe G, Petersen L, Albrektsen T et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004; 103:3029-3037. (Pubitemid 38451676)
25. Albrektsen T, Sørensen B, Hjortø G et al. Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J Thromb Haemost 2007; 5:1588-1597. (Pubitemid 47091396)
26. Shoji M, Abe K, Nawroth P et al. Molecular Mechanisms Linking Thrombosis and Angiogenesis in Cancer. Trends Cardiovasc Med 1997; 7:52-59. (Pubitemid 27131724)
27. Abe K, Shoji M, Chen J et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A 1999; 96:8663-8668. (Pubitemid 29354848)
28. Armesilla A, Lorenzo E, Gómez del Arco P et al. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression. Mol Cell Biol 1999; 19:2032-2043. (Pubitemid 29098261)
29. Nakasaki T, Wada H, Shigemori C et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002; 69:247-254. (Pubitemid 34259846)
30. Shigemori C, Wada H, Matsumoto K et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998; 80:894-898. (Pubitemid 28556688)
31. Kim I, Oh J-L, Ryu Y et al. Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells. FASEB J 2002; 16:126-128.
32. Reinhardt C, Bergentall M, Greiner T et al. Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling. Nature 2012; 483(7391):627-631.
33. Versteeg H, Schaffner F, Kerver M et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008; 111:190-199.
34. Ruf W, Miles D, Rehemtulla A et al. Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII. J Biol Chem 1992; 267:22206-22210.
35. Ruf W, Mueller B. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 1996; 3:379-3784
36. Nagy J, Brown L, Senger D et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989; 948:305-326. (Pubitemid 19055388)
37. Wojtukiewicz M, Tang D, Nelson K et al. Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. Thromb Res 1992; 68:233-245.
38. Stenberg P, McEver R, Shuman et al. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101:880-886. (Pubitemid 16256841)
39. Henn V, Slupsky J, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391(6667):591-594. (Pubitemid 28157601)
40. Zucker S, Mirza H, Conner C et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998; 75:780-786. (Pubitemid 28145828)
41. Nierodzik M, Kajumo F, Karpatkin S. Effect of Thrombin Treatment of Tumor Cells on Adhesion of Tumor Cells to Platelets in Vitro and Tumor Metastasis in Vivo. Cancer Res 1992; 52:3267-3272.
42. Förster Y, Meye A, Albrecht S et al. Tissue factor and tumor: Clinical and laboratory aspects. Clin Chim Acta 2006; 364:12-21. (Pubitemid 43120625)
43. Jy W, Horstman L, Jimenez J et al. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2:1842-1843.
44. Key N, Mackman N. Tissue factor and its measurement in whole blood, plasma, and microparticles. Semin Thromb Hemost 2010; 36:865-875.
45. Parhami-Seren B, Butenas S, Krudysz-Amblo J et al. Immunologic quantitation of tissue factors. J Thromb Haemost 2006; 4:1747-1755. (Pubitemid 44144802)
46. Zwicker J. Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost 2008; 34:195-198.
47. Mostefai H, Andriantsitohaina R, Martínez M. Plasma membrane micropartides in angiogenesis: role in ischemic diseases and in cancer. Physiol Res 2008; 57:311-320.
48. Enjeti A, Lincz L, Seldon M. Microparticles in health and disease. Semin Thromb Hemost 2008; 34:683-691.
49. Bacharach E, Itin A, Keshet E. In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sci U S A 1992; 89:10686-10690.
50. Thunø M, Macho B, Eugen-Olsen J. SuPAR: the molecular crystal ball. Dis Markers 2009;27:157-172.
51. Schmitt M, Harbeck N, Thomssen C et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78:285-296. (Pubitemid 27289256)
52. Korte W. Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures. Clin Chem Lab Med 2000; 38:679-692.
53. Lugassy G, Klepfish A. The fibrinolytic system in cancer. In: Lugassy G, Falanga A, Kakkar AK, Rickles FR (Eds): Thrombosis and cancer. London, Martin Dunitz, 2004, Ch5, pp 61-63.
54. Harbeck N, Schmitt M, Kates R et al. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin Breast Cancer 2002; 3:196-200.
55. Eugen-Olsen J, Gustafson P, Sidenius N et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002; 6:686-692. (Pubitemid 34832148)
56. Langkilde A, Hansen T, Ladelund S et al. Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. Cancer Epidemiol Biomarkers Prev 2011; 20:609-618.
57. Stephens R, Nielsen H, Christensen I et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91:869-874. (Pubitemid 29252303)
58. Riisbro R, Stephens R, Brünner N et al. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol 2001; 82:523-531. (Pubitemid 32826454)
59. Riisbro R, Christensen I, Piironen T et al. Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Serum and Cytosol of Tumor Tissue from Patients with Primary Breast Cancer. Clin Cancer Res 2002; 8:1132-1141. (Pubitemid 34517650)
60. Aref S, El-Sherbiny M, Mabed M et al. Urokinase Plasminogen Activator Receptor and Soluble Matrix Metalloproteinase-9 in Acute Myeloid Leukemia Patients: A Possible Relation to Disease Invasion. Hematology 2003; 8:385-391. (Pubitemid 38088326)